Oligomeric vaccines
Immunization is an important tool to fight diseases caused by viral, bacterial or fungal pathogenes. The invention provides a new approach for the generation of oligomeric vaccines. The underlying principle is the high affinity interaction between S-protein and a modified S-tag of bovine pancreatic RNase A which is applied to hemagglutinin (H5). The technology can be applied to produce high molecular vaccines. They have many advantages compared to recently used vaccines including high immunogenicity, high stability, short production time and lower production costs. The approach could therefore be used for the immunization of livestock.
Further information: PDF
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Phone: +49 (0)391/8 10 72 20
Contact
Dr. Detlef Förster
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
Simplified diagnosis of rare eye diseases
Uveitis experts provide an overview of an underestimated imaging technique. Uveitis is a rare inflammatory eye disease. Posterior and panuveitis in particular are associated with a poor prognosis and a…
Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma
New study identifies NECTIN4 amplification as a promising biomarker – Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn…